Article
Neurosciences
Alexander S. Mihaescu, Mikaeel Valli, Carme Uribe, Maria Diez-Cirarda, Mario Masellis, Ariel Graff-Guerrero, Antonio P. Strafella
Summary: The deposition of beta amyloid in specific brain regions has a moderate effect on predicting future cognitive decline in Parkinson's disease patients, and may contribute to the difference between cognitive impairment and cognitive sparing.
Article
Clinical Neurology
Lei Liu, Bianca M. Lauro, Amy He, Hyo Lee, Sanjay Bhattarai, Michael S. Wolfe, David A. Bennett, Celeste M. Karch, Tracy Young-Pearse, Dennis J. Selkoe
Summary: This study aims to identify biomarkers for Alzheimer's disease (AD) and finds that the A beta 37/42 ratio can be used to distinguish AD from normal aging. Experimental results show that this ratio outperforms the traditional ratio in differentiating physiological and pathological states in cell culture, brain tissue, and cerebrospinal fluid. The findings may provide a new indicator for early diagnosis of AD.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Roland Nicsanu, Carlo Cervellati, Luisa Benussi, Rosanna Squitti, Roberta Zanardini, Valentina Rosta, Alessandro Trentini, Clarissa Ferrari, Claudia Saraceno, Antonio Longobardi, Sonia Bellini, Giuliano Binetti, Orazio Zanetti, Giovanni Zuliani, Roberta Ghidoni
Summary: This study investigated the role of serum BACE1 activity as a biomarker for Alzheimer's disease (AD). Results showed that BACE1 levels were increased in AD and MCI-AD patients and could accurately discriminate patients with high sensitivity and specificity. High BACE1 levels were associated with worse cognitive performance and earlier disease onset.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Review
Clinical Neurology
Dongcheng Li, Tengzhu Ren, Hao Li, Geng Liao, Xiong Zhang
Summary: Cognitive impairment is a common complication of Parkinson's disease, and the convergence of alpha-Synuclein and Alzheimer's disease-like pathologies, neuroinflammation, and dysbiosis of gut microbiota are major features of Parkinson's disease with cognitive impairment. Recent research suggests a potential role of Porphyromonas gingivalis in the pathogenesis of both Parkinson's disease and Alzheimer's disease, particularly in relation to neuroinflammation and the deposition of alpha-Synuclein and amyloid-beta.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Bartlomiej Stanczykiewicz, Tomasz M. Goszczynski, Pawel Migdal, Marta Piksa, Krzysztof Pawlik, Jakub Gburek, Krzysztof Golab, Boguslawa Konopska, Agnieszka Zablocka
Summary: The research aims to determine the inhibitory activity of ovocystatin, a cysteine protease inhibitor isolated from egg white, on A beta 42 fibril formation in vitro. The results show that ovocystatin possesses A beta 42 anti-aggregation activity and inhibits A beta 42 oligomer toxicity in PC12 cells. This research may contribute to the development of potential substances to prevent or delay beta-amyloid aggregation, a major cause of Alzheimer's disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Yunna Kim, Seung-Hun Cho
Summary: The study showed that Lindera glauca can improve cognitive impairments induced by A beta(1-42), reduce pathological protein deposition, and promote neuroprotection.
NEUROCHEMISTRY INTERNATIONAL
(2021)
Article
Clinical Neurology
Michela Garon, Luca Weis, Eleonora Fiorenzato, Francesca Pistonesi, Annachiara Cagnin, Alessandra Bertoldo, Mariagiulia Anglani, Diego Cecchin, Angelo Antonini, Roberta Biundo
Summary: This study investigated the impact of beta-amyloid (Aβ) on the clinical and cognitive manifestations as well as regional brain volumes in Parkinson's disease with mild cognitive impairment (PD-MCI). The results showed that the presence of Aβ worsened executive functions in PD-MCI patients, but did not affect motor and global cognitive abilities. Aβ deposition was found in specific brain regions, and higher amyloid load correlated with worse executive performances. However, Aβ may not be the main cause of cognitive deterioration in PD-MCI.
FRONTIERS IN NEUROLOGY
(2022)
Article
Neurosciences
Gege Jiang, Zhenzhen Long, Yaoling Wang, Yaofeng Wang, Ping Xue, Minfang Chen, Kang Yang, Wei Li
Summary: The reduction of LRP1 in brain microvascular endothelial cells (BMECs) is a key factor leading to amyloid-beta (ABeta) deposition in the brain and diabetic cognitive impairment. Inhibiting mTORC1 and SREBP1 activation can improve ABeta efflux under high-glucose stimulation and alleviate cognitive impairment.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Immunology
Lieke Bakker, Sebastian Kohler, Simone J. P. M. Eussen, Kyonghwan Choe, Daniel L. A. van den Hove, Gunter Kenis, Bart P. F. Rutten, Arve Ulvik, Per M. Ueland, Frans R. J. Verhey, Inez H. G. B. Ramakers
Summary: This study investigated the correlations between kynurenines in plasma and cerebrospinal fluid (CSF) and their associations with AD pathology. The results showed moderate to strong correlations between certain kynurenines in plasma and CSF, and higher kynurenine levels were related to lower AD pathology load. These findings need further verification and more research into the underlying mechanisms.
BRAIN BEHAVIOR AND IMMUNITY
(2023)
Article
Multidisciplinary Sciences
Pai-Yi Chiu, Fu-Chi Yang, Ming-Jang Chiu, Wei-Che Lin, Cheng-Hsien Lu, Shieh-Yueh Yang
Summary: This study investigated the combination of different biomarkers in AD, PD, and FTD and found that plasma biomarkers were consistent with pathology. This provides promise for the precise assessment of AD, PD, and FTD in clinical practice.
SCIENTIFIC REPORTS
(2022)
Article
Psychiatry
Xiao-Yu He, Kevin Kuo, Liu Yang, Ya-Ru Zhang, Bang-Sheng Wu, Shi-Dong Chen, Wei Cheng, Jian-Feng Feng, Jin-Tai Yu
Summary: This study investigates the association between common serum laboratory tests and the risk of incident dementia. Results show that low vitamin D concentration, endocrine disorders, reduced liver and renal function, oxidative stress, dysregulated lipids, insulin resistance, and immune dysbiosis are associated with the onset of dementia.
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Biochemistry & Molecular Biology
Marten Beeg, Elisabetta Battocchio, Ada De Luigi, Laura Colombo, Carmina Natale, Alfredo Cagnotto, Alessandro Corbelli, Fabio Fiordaliso, Luisa Diomede, Mario Salmona, Marco Gobbi
Summary: Nonphosphorylated tau protein can inhibit the elongation of Aβ(1-42) fibrils and structurally affect the aggregation process of Aβ. In in vivo experiments, tau monomers bind to Aβ(1-42) oligomers, hinder their interaction with anti-Aβ antibodies, and provide neuroprotective effects by shielding the hydrophobic patches on Aβ(1-42) oligomers.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Food Science & Technology
Zhipeng Kan, Yijun Wang, Qian Chen, Xiaoyu Tang, Henry J. Thompson, Jinbao Huang, Jinsong Zhang, Feng Gao, Yong Shen, Xiaochun Wan
Summary: In this study, it was found that green tea extract treatment significantly improved spatial learning and memory ability in 5XFAD mice, reduced the formation of A beta, and decreased the levels of related proteins. GTE also suppressed glial cell activation and inflammatory responses, while increasing synaptic protein levels.
MOLECULAR NUTRITION & FOOD RESEARCH
(2021)
Article
Clinical Neurology
Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh
Summary: The study found that the changes in CSF alpha-syn, t-tau, and p-tau were not significant enough to distinguish PD patients with and without RBD. However, CSF A beta 1-42 decreased in the short term and showed a significant difference after a while in PD patients with and without RBD.
JOURNAL OF NEUROLOGY
(2022)
Article
Nutrition & Dietetics
Yacoubou Abdoul Razak Mahaman, Jun Feng, Fang Huang, Maibouge Tanko Mahamane Salissou, Jianzhi Wang, Rong Liu, Bin Zhang, Honglian Li, Feiqi Zhu, Xiaochuan Wang
Summary: Alzheimer's disease is a global health problem with no effective single therapy. Nutraceutical agents like Moringa oleifera (MO), which have multiple effects, show promise in treating AD. This study found that MO treatment improved behavioral and cognitive deficits, reduced A beta burden, and improved synaptic plasticity and neurodegeneration in AD mice.
Review
Clinical Neurology
Daniel Weintraub, Dag Aarsland, Kallol Ray Chaudhuri, Roseanne D. Dobkin, Albert F. G. Leentjens, Mayela Rodriguez-Violante, Anette Schrag
Summary: Neuropsychiatric signs and symptoms are common in people with Parkinson's disease, and their underlying neurobiology is complex. Identifying risk factors and developing effective treatments require further research and specialized care models.
Article
Clinical Neurology
Thomas Guttuso, Daniel Sirica, Duygu Tosun, Robert Zivadinov, Ofer Pasternak, Daniel Weintraub, Francesca Baglio, Niels Bergsland
Summary: This study assessed the free water content changes in cognitive-relevant brain regions in early Parkinson's disease patients and their correlation with cognitive decline over time and baseline cognitive status. Results showed that free water was the most robust assessment modality for these outcomes and may assist in identifying cognition protective therapies in clinical trials.
MOVEMENT DISORDERS
(2022)
Article
Neurosciences
Hannah Staunton, Kim Kelly, Louise Newton, Mathias Leddin, Raul Rodriguez-Esteban, K. Ray Chaudhuri, Daniel Weintraub, Ronald B. Postuma, Pablo Martinez-Martin
Summary: This study aims to create a conceptual model of symptoms and impacts for individuals with early-stage Parkinson's disease (PD) by collecting qualitative data. The results show that the most frequently reported symptoms in early-stage PD include tremors, stiffness and rigidity, and fatigue, while the most commonly reported impacts include anxiety, eating and drinking, and exercise/sport and relationship with family/family life. The conceptual model can be used to guide researchers in developing and selecting patient-centered outcomes for clinical trials and inform future qualitative research and outcome development specifically for early-stage PD patients.
JOURNAL OF PARKINSONS DISEASE
(2022)
Article
Clinical Neurology
Maiko Takahashi, Jinsoo Koh, Shoko Yorozu, Yoshinori Kajimoto, Yoshiaki Nakayama, Mayumi Sakata, Masaaki Yasui, Yasuhiro Hiwatani, Daniel Weintraub, Hidefumi Ito
Summary: The present study validated the Japanese version of QUIP-RS and determined the characteristics of ICBs in Japan. The use of QUIP-RS-J enables standardized assessment of ICBs and can be used in clinical research.
PARKINSONS DISEASE
(2022)
Article
Clinical Neurology
Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw
Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Clinical Neurology
John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee
Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article
Clinical Neurology
Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis
Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.
Article
Clinical Neurology
Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea
Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Neurosciences
Kalpana M. Merchant, Tanya Simuni, Janel Fedler, Chelsea Caspell-Garcia, Michael Brumm, Kelly N. H. Nudelman, Elizabeth Tengstrandt, Frank Hsieh, Roy N. Alcalay, Christopher Coffey, Lana Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline Tanner, Ken Marek
Summary: We quantified concentrations of three isoforms of BMP in different cohorts of Parkinson's disease patients and found that LRRK2 and GBA1 gene mutations were associated with elevated BMP levels. However, BMP is not a prognostic or disease progression biomarker.
NPJ PARKINSONS DISEASE
(2023)
Article
Clinical Neurology
Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Cornelis Blauwendraat, Ethan G. Brown, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, Doug Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Tanya Simuni, Andrew Siderowf, Andrew Singleton, John Seibyl, Caroline M. Tanner
Summary: This study used data from a multi-site, international, prospective cohort study to investigate the impact of dopamine system-related biomarkers on cognitive impairment in Parkinson's disease. The results showed that alterations in the dopamine system were associated with the development of cognitive impairment in Parkinson's disease. If confirmed causative, these findings suggest that the dopamine system is instrumental to cognitive health status throughout the disease course.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Daniel Weintraub
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney
Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Clinical Neurology
Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis
Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Clinical Neurology
Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Daniel Weintraub
MOVEMENT DISORDERS
(2023)